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In the last two decades it has been demonstrated that radioiodine
(
 
131
 
I) is an effective therapy for thyroid volume reduction in
patients with toxic and nontoxic nodular goitre. In these patients,
 
131
 
I treatment leads to a significant decrease in goitre size. In most
patients compressive symptoms improve as well. The decrease
in compressive symptoms is accompanied by significant tracheal
widening and improvement of respiratory function (for review
see Hegedüs 
 
et al
 
., 2003).
 
131
 
I treatment is especially attractive in elderly patients who
have a high operative risk and in those who refuse surgery.
However, in patients with nontoxic, nodular goitre thyroid radio-
active iodide uptake (RAIU) is usually rather low, especially
in areas with a high iodine intake. As a result, high doses of 
 
131
 
I
are often needed for thyroid volume reduction, causing a relatively
high radiation burden to extrathyroidal organs (Huysmans 
 
et al
 
.,
1996). Therefore, it is of interest to explore strategies to enhance
RAIU in these patients. In the last decade recombinant human
thyrotropin (rhTSH) has become available for diagnostic use in
patients with differentiated thyroid cancer. It has been shown that
rhTSH stimulates RAIU in thyroid remnants and thyroid cancer
tissue (Ladenson 
 
et al
 
., 1997; Haugen 
 
et al
 
., 1999). Recently, we
reported that rhTSH stimulates RAIU also in patients with
nodular goitre: the administration of a single, low dose of 0·01 or
0·03 mg rhTSH doubled 24-h RAIU in these patients (Huysmans
 
et al
 
., 2000). Pretreatment with rhTSH also caused a more homo-
geneous distribution of radioiodine on the thyroid scintigrams
of nodular goitres by stimulating radioiodide uptake in relatively
cold areas more than in relatively hot areas, especially in patients
with a low baseline serum TSH level (Nieuwlaat 
 
et al
 
., 2001).
These observations suggest that administration of rhTSH before
 
131
 
I therapy for volume reduction of nodular goitre may allow
treatment with lower doses of 
 
131
 
I without diminishing the radiation-
absorbed dose in the thyroid and the efficacy of this mode of
therapy. Indeed, pretreatment with a single, low dose of 0·01 or
0·03 mg rhTSH allowed approximately 50–60% reduction of the
therapeutic dose of radioiodine without compromising the effi-
cacy of thyroid volume reduction (Nieuwlaat 
 
et al
 
., 2003). As the
radiation burden of radioiodine therapy to extrathyroidal organs
is directly related to the administered 
 
131
 
I dose (Huysmans 
 
et al
 
.,
1996), such a dose reduction may render radioiodine therapy
more attractive for younger patients and may allow for more
patients to be treated on an out-patient basis.
A major drawback of radioiodine therapy for nodular goitre
(with 
 
131
 
I doses aimed at approximately 100–150 
 
µ
 
Ci retained
per gram of thyroid tissue at 24 h) is that mean thyroid volume
reduction is not greater than approximately 40% after 1 year, and
50–60% after 3–5 years (for review see Hegedüs 
 
et al
 
., 2003).
Moreover, not all patients respond. Preliminary data by Le Moli
 
et al
 
. (1999) suggest that goitre reduction can be augmented by
increasing the radiation-absorbed dose in the thyroid. Such an
increase can be achieved by simply enlarging the administered
dose of radioiodine, but this will further increase the radiation
burden to extrathyroidal organs. Alternatively, it should be possible
to increase the radiation-absorbed dose in the thyroid without
increasing the administered dose of radioiodine, by stimulating
RAIU using pretreatment with rhTSH.
In this issue of 
 
Clinical Endocrinology
 
, Silva 
 
et al
 
. (2004) report
a study in which 34 patients with large, nodular goitres (22 were
subclinically hyperthyroid and seven overtly hyperthyroid) were
randomized to radioiodine therapy alone or to radioiodine ther-
apy in comparable doses but with pretreatment with a relatively
high dose of rhTSH (0·45 mg), given 24 h before radioiodine
administration. Patients pretreated with rhTSH had a signifi-
cantly larger thyroid volume reduction after 1 year (58 
 
±
 
 13%;
mean 
 
±
 
 SD) than patients given radioiodine without rhTSH
pretreatment (40 
 
±
 
 12%).
From data provided in Tables 1 and 2 of their report, we
calculated the dose retained in the thyroid at 24 h for individual
patients in both groups. This parameter was considerably higher
in the rhTSH-pretreated patients (191 
 
±
 
 75 
 
µ
 
Ci/g of thyroid
tissue) than in the patients not pretreated with rhTSH (73 
 
±
 
 22
 
µ
 
Ci/g). It seems likely that the higher thyroid volume reduction
in the rhTSH-pretreated group can be explained by the higher
retention of radioiodine in the thyroid. An alternative explanation
is that pretreatment with rhTSH improves thyroid volume reduc-
tion by causing a more homogeneous distribution of radioiodine
within the thyroid, especially increasing the uptake of radio-
iodine in relatively cold areas (Nieuwlaat 
 
et al
 
., 2001).
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It may be anticipated that a higher dose of radioiodine retained
in the thyroid will be accompanied by more severe early adverse
effects due to radiation-induced thyroiditis and oesophagitis.
Indeed, in comparison with patients not pretreated with rhTSH,
rhTSH-pretreated patients had a higher incidence of pain in the
thyroid region (52% 
 
vs.
 
 23%), complaints due to oesophagitis
(17% 
 
vs.
 
 11%) and weight loss (65% 
 
vs.
 
 52%).
Another consequence of thyroiditis is acute enlargement of
the thyroid gland with (further) compression of the trachea. For
radioiodine doses aimed at approximately 100–150 
 
µ
 
Ci retained
per gram of thyroid tissue at 24 h, increases in thyroid volume
1 week after radioiodine therapy up to 25% have been found
(Nygaard 
 
et al
 
., 1994; Bonnema 
 
et al
 
., 1999; Nieuwlaat 
 
et al
 
.,
2003). Silva 
 
et al.
 
 (2004) did not quantify thyroid volume changes
in the first period after radioiodine therapy. Therefore, it remains
to be investigated whether the larger 
 
131
 
I doses retained in the
thyroid as used by Silva 
 
et al.
 
 (2003) cause larger increases in
thyroid volume in the first period after radioiodine treatment.
Mild increases in serum thyroid hormone levels due to radiation-
induced thyroiditis are commonly seen in the first weeks after
radioiodine treatment of nodular goitre, with maximum levels
reached at approximately 2 weeks after therapy (Nygaard 
 
et al
 
.,
1994). It has also been demonstrated that administration of low
doses of rhTSH (0·01 or 0·03 mg) in patients with nodular
goitre results in mild increases in serum thyroid hormone levels,
with maximum levels reached at 1–4 days after administration
of rhTSH (Huysmans 
 
et al
 
., 2000). It may be anticipated that
pretreatment with a relatively high dose of rhTSH followed by
a full dose of radioiodine, leading to a high radiation-absorbed
dose in the thyroid, will result in larger increases in serum thyroid
hormone levels. Indeed, peak FT4 levels reached in the rhTSH-
pretreated patients studied by Silva 
 
et al.
 
 (2004) were much higher
than those in the patients treated with radioiodine alone (59 
 
±
 
 22
 
vs.
 
 24 
 
±
 
 7 pmol/ l), despite a low-iodine diet in all patients and
methimazole pretreatment in the seven overtly hyperthyroid
patients. The highest FT4 levels were reached already at 1–3 days
after radioiodine therapy, suggesting that rhTSH administration
was the most important cause of the rise. Fortunately, no hyper-
thyroid symptoms or worsening of heart diseases were observed.
The authors give three possible explanations: the rise in thyroid
hormone levels was of short duration, most patients had cardiac
medications, and all patients were confined to their beds for 5–
9 days after radioiodine therapy.
A late adverse effect of radioiodine treatment of nodular goitre
is development of hypothyroidism. Probably related to the higher
radioiodine dose retained in the thyroid, Silva 
 
et al.
 
 (2004) found
that hypothyroidism 1 year after radioiodine therapy was more
frequent in the rhTSH-pretreated patients than in the patients not
pretreated with rhTSH (65% 
 
vs.
 
 21%).
The study of Silva 
 
et al.
 
 (2004) is the first to show that the
efficacy of radioiodine therapy of nodular goitres can be
improved by pretreatment with rhTSH. However, conclusions are
based on small numbers of patients and both toxic (four of them
had used amiodarone) and nontoxic patients were included.
Moreover, no attempt was made to calculate precisely the radio-
iodine doses to be administered (radioiodine doses were based
on a rather simple algorithm with estimated thyroid volume as
the only parameter).
Before rhTSH can be advised as an adjunct to improve the effi-
cacy of radioiodine therapy in nodular goitre, further studies are
needed. First, it has to be determined in a formal dose–response
study which dose of rhTSH is optimal for this purpose. Such a dose
should stimulate RAIU considerably, but should not cause unac-
ceptable rises in serum thyroid hormone levels. Then, radioiodine
therapy with and without pretreatment with that particular dose
of rhTSH should be investigated in randomized studies. Such
studies should look carefully at dose–response relationships with
respect to efficacy and adverse effects. Given the heterogeneity
of nodular goitres, large groups of patients will be needed.
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